Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2013 Dec 9;14(2):155–162.e1. doi: 10.1016/j.clml.2013.08.008

Table 4.

Long Term Outcome

Outcome Percentage at 36 months
EFS TFS FFS OS
Overall 86 93 71 89
 Imatinib 91 96 70 87
 2GTKI 78 90 73 95
12-months CCyR 96 100 88 100
No CCyR 75 100 75 100
18-months MMR 100 100 90 100
No MMR 75 100 75 100

CCyR, Complete Cytogenetic Response; MMR, Major Molecular Response; 2GTKI, Second Generation tyrosine kinase inhibitor; EFS, Event Free Survival; TFS, Transformation Free Survival; FFS, Failure Free Survival; OS, Overall Survival